Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)

被引:0
作者
Charles W. Lynde
Maryam S. Alam
Kamal Ohson
Angélique Gagné-Henley
Miriam Avadisian
Ronald B. Vender
机构
[1] Lynderm Research Inc.,
[2] SimcoMed Health Ltd,undefined
[3] Karma Clinical Trials Inc.,undefined
[4] Memorial University of Newfoundland (MUN),undefined
[5] Dre Angélique Gagné-Henley M.D. Inc.,undefined
[6] AbbVie Corporation,undefined
[7] Dermatrials Research Inc.,undefined
来源
Dermatology and Therapy | 2022年 / 12卷
关键词
Adalimumab; Canada; Dermatology; Effectiveness; Observational; Psoriasis; Topical; Traditional systemic;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:921 / 931
页数:10
相关论文
共 50 条
[1]  
Sivamani RK(2010)Biological therapy of psoriasis Indian J Dermatol. 55 161-70
[2]  
Correa G(2020)Global burden of psoriasis—comparison of regional and global epidemiology, 1990 to 2017 Int J Dermatol. 59 566-71
[3]  
Ono Y(2014)Psoriasis prevalence among adults in the United States J Am Acad Dermatol 70 512-516
[4]  
Bowen MP(2019)Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study Arthritis Care Res (Hoboken) 71 1084-1091
[5]  
Raychaudhuri SP(2016)2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009 J Cutan Med Surg 20 375-431
[6]  
Maverakis E(2018)Psoriasis, cardiovascular events, and biologics: lights and shadows Front Immunol 9 1668-158
[7]  
AlQassimi S(2013)Psoriasis CMAJ 185 E174-566
[8]  
AlBrashdi S(2018)Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience Ther Adv Chronic Dis 9 147-381
[9]  
Galadari H(2008)Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 558-1559
[10]  
Hashim MJ(2017)Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry Dermatol Ther (Heidelb) 7 365-1166